• CABAZITAXEL chembl:CHEMBL1201748 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    JEVTANA
    CABAZITAXEL
    TXD 258
    CABAZITAXEL ACETONATE
    TXD-258
    JEVTANA KIT
    XRP 6258
    XRP-6258
    TXD258
    XRP6258
    CABAZITAXELUM
    JEVANTA®
    TAXOID XRP6258
    chembl:CHEMBL1201748
    drugbank:06772
    pubchem.compound:9854073
    chemidplus:183133-96-2
    rxcui:996051

    Drug Info:

    FDA Approval approved
    Drug Class Small molecule
    Drug Indications antineoplastic agent
    Drug Class antineoplastic agent
    Year of Approval 2010
    Drug Categories terpenes
    Drug Categories taxoids
    Drug Categories taxane derivatives
    Drug Categories polycyclic compounds
    Drug Categories p-glycoprotein/abcb1 substrates
    Drug Categories p-glycoprotein/abcb1 inhibitors
    Drug Categories organic chemicals
    Drug Categories myelosuppressive agents
    Drug Categories macrocyclic compounds
    Drug Categories immunosuppressive agents
    Drug Categories hydrocarbons, cyclic
    Drug Categories hydrocarbons, alicyclic
    Drug Categories hydrocarbons
    Drug Categories diterpenes
    Drug Categories cytochrome p-450 cyp3a4 substrates
    Drug Categories cytochrome p-450 cyp2c8 substrates
    Drug Categories cycloparaffins
    Drug Categories cyclodecanes
    Drug Categories bcrp/abcg2 inhibitors
    Drug Categories antineoplastic and immunomodulating agents
    Drug Categories antineoplastic agents
    Drug Groups approved
    Drug Type small molecule
    Drug Categories p-glycoprotein substrates with narrow therapeutic index
    Drug Categories p-glycoprotein substrates
    Drug Categories p-glycoprotein inhibitors
    Drug Categories oatp1b3 inhibitors
    Drug Categories oatp1b1/slco1b1 inhibitors
    Drug Categories microtubule inhibitors
    Drug Categories microtubule inhibition
    Drug Categories cytochrome p-450 substrates
    Drug Categories cytochrome p-450 cyp3a5 substrates
    Drug Categories cytochrome p-450 cyp3a substrates
    Drug Categories cardiotoxic antineoplastic agents
    (5 More Sources)
  • Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Tubulin inhibitor
    Direct Interaction yes

    Publications:

  • Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Tubulin inhibitor
    Direct Interaction yes
    Specific Action of the Ligand Inhibition

    Publications:

  • Interaction Types & Directionality:
    binder
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name cabazitaxel, XRP6258,Jevtana
    Novel drug target Established target
    Mechanism of Interaction Tubulin inhibitor

    Publications:

  • Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Tubulin inhibitor

    Publications:

  • Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Tubulin inhibitor
    Direct Interaction yes

    Publications:

  • Interaction Types & Directionality:
    binder
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name cabazitaxel, XRP6258,Jevtana
    Novel drug target Established target
    Mechanism of Interaction Tubulin inhibitor

    Publications:

  • Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Tubulin inhibitor

    Publications:

  • Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Tubulin inhibitor

    Publications:

  • Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Tubulin inhibitor
    Direct Interaction yes

    Publications:

  • Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Tubulin inhibitor

    Publications:

  • Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Tubulin inhibitor
    Direct Interaction yes

    Publications:

  • Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Tubulin inhibitor

    Publications:

  • Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Tubulin inhibitor
    Direct Interaction yes

    Publications:

  • Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Tubulin inhibitor
    Direct Interaction yes

    Publications:

  • Interaction Types & Directionality:
    n/a

    Interaction Info:

    Publications:

  • Interaction Types & Directionality:
    n/a

    Interaction Info:

    Publications:

    • Version: 01-August-2011

    Alternate Names:
    CABAZITAXEL Primary Drug Name

    Drug Info:
    Year of Approval 2010
    Drug Class antineoplastic agent

    Publications:

    • Version: 5.1.7

    Alternate Names:
    CABAZITAXEL DrugBank Drug Name
    183133-96-2 CAS Number
    Cabazitaxel for Injection Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Categories antineoplastic agents

    Publications:

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small molecule
    FDA Approval approved

    Publications:

  • Alternate Names:
    CABAZITAXEL GuideToPharmacology Ligand Name

    Drug Info:

    Publications:

    • Version: 2020.06.01

    Alternate Names:
    D02HSB TTD Drug ID

    Drug Info:

    Publications:

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications: